Regenerative Medicine and Stem Cells Technologies

Adding to the flurry of gene-therapy deals, Pfizer has paid roughly $51 million for a 15% stake in Vivet Therapeutics, which is developing liver-directed gene therapies.

After 10 years in remission, Derek Ruffs cancer returned, this time as stage IV colon cancer. Despite aggressive rounds of chemotherapy, palliative radiotherapy and immunotherapy, his disease progressed.

NIBIB-funded researchers have developed a 3-D-printed scaffold coated in aggrecan, a native cartilage component, to improve the regeneration of cartilage tissue in joints.

New research led by scientists at Newcastle University, UK reveals a potential revolutionary way to treat eye injuries and prevent blindness—by softening the tissue hosting the stem cells which then helps repair wounds, inside the body.

As cancer cells respond to cues in their microenvironment, they can enter a highly plastic state in which they are susceptible to transdifferentiation into a different type of cell.

Nearly 75,000 Americans need an organ transplant. Of those, an estimated 18 will die today because they didn’t get one soon enough.

The gene editing technique known as CRISPR is a revolutionary approach to treating inherited diseases. However, the tool has yet to be used to effectively treat long-term, chronic conditions.

The World Health Organization’s new advisory committee on developing global standards for governance and oversight of human genome editing has agreed to work towards a strong international governance framework in this area.

Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

Sacks of pungent animal feed cram the corridors of a Cyagen Biosciences Inc. center for laboratory mice in southern China, maximizing space for rodents that sell for as much as $17,000 a pair.